Anti-CD33 Antibody-drug Conjugate BL-M11D1 clinical trials
Its developmentBy Sichuan Biokin Pharmaceutical, step by step4 company-led studies, furthest phase 3: when each phase was reached, its deals, target and what is ahead.How each study uses Anti-CD33 Antibody-drug Conjugate BL-M11D1 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Anti-CD33 Antibody-drug Conjugate BL-M11D1 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- BL-M11D1
- 4
Studies by the year they started
4 studies that test it; most in 2026 (2)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Sichuan Baili Pharmaceutical Co., Ltd. (3) · SystImmune Inc. (1)
Often tested with
Tested in the same studies.
Cytarabine (1) · Daunorubicin (1) · Venetoclax (1) · Azacitidine (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Anti-CD33 Antibody-drug Conjugate BL-M11D1.
- Dec 2026A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid LeukemiaPhase 1 · Sichuan Baili Pharmaceutical Co., Ltd.
Studies
Open first, then newest update. How each study uses Anti-CD33 Antibody-drug Conjugate BL-M11D1 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid LeukemiaRecruitingPhase 2/3Sichuan Baili Pharmaceutical Co., Ltd.NCT07255872Written as BL-M11D1How we know
- A Study of BL-M11D1 in Patients With Relapsed/Refractory Myelodysplastic SyndromesNot yet recruitingPhase 1/2Sichuan Baili Pharmaceutical Co., Ltd.NCT07591168Written as BL-M11D1How we know
- A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid LeukemiaRecruitingPhase 1Sichuan Baili Pharmaceutical Co., Ltd.NCT05924750Written as BL-M11D1How we know
- Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1TerminatedPhase 1SystImmune Inc.NCT06714591Written as BL-M11D1How we know